The demand for GLP1-RA approved for obesity is high so there have even been supply shortages in Europe.1 Since the prevalence of both overweight and obesity among women of childbearing age is increasing substantially in most countries (between 30% in some European countries and nearly 50% in the USA), it is to be expected that a further growing number of women of reproductive age will be treated with GLP1-RA.2–4 Approximately 50% of pregnancies worldwide are unplanned5; therefore, the question of the safety of GLP1-RA is particularly relevant. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.